On January 5, 2020, "China’s First Mechanical Circulatory Support Conference" and "The First Preparatory Meeting of Mechanical Circulatory Support (MCS) Branch of Chinese Society of Biomedical Engineering (CSBE) " sponsored by National Center for Cardiovascular Diseases (NCCD) and Fuwai Hospital were held in Beijing. The event invited experts from National Center for Medical Device Evaluation (NCMDE), National Medical Products Administration (NMPA) and National Institute for Food and Drug Control (NIFDC), universities, main enterprises, research institutions in the field of mechanical circulatory support, and more than 50 domestic surgical expert teams of large heart centers. Our CEO Dr. Chen was invited to participate in the meeting and give keynote speech as a representative of the research and development enterprises.
The meeting focused on the society preparation work, operation system and plan of the Mechanical Circulation Support Branch of CSBE. It also discussed on how to accelerate the clinical transformation of medical device research and development in this field and improve the clinical application effect of mechanical circulatory support devices. At the meeting, Dr. Chen delivered a keynote speech titled "Current Status and Future of Implantable Ventricle Assist Device". He introduced the market dynamics and technological evolution of VAD and analyzed the future development trend. At the same time, he shared the latest clinical application and test results of CH-VAD® of CH Biomedical, which gained high attention from the participants.
Dr. Chen is one of the founding members of the mechanical circulatory support branch of CSBE which consists of experts of regulation, industry, academy, and healthcare system in the field.
Through the establishment of an exchange platform in this field, experts in various fields of technology and clinical medicine will be gathered to strengthen interdisciplinary, multi-field, and cross-cutting innovative research to help our country's R&D and manufacturing capabilities of mechanical circulatory support.
May 24-27, 2022 International Society for Mechanical Circulatory Society (ISMCS) and European Mechanical Circulatory Society (EUMS) Joint Scientific Conference was successfully held in Hanover, Germany. Dr. Frank Lin, PhD, CTO of CH Biomedical, and Mr. Karl Nelson, Vice President of Clinical Operations were invited to attend the conference.
On November 25th 2021, the implantable CH-VAD® left ventricular assist system (CH-VAD® LVAS) of CH Biomedical was approved by the National Medical Products Administration (NMPA) for marketing (Registration No.: GXZZ 20213120987). CH-VAD LVAS was developed independently by CH Biomedical, it is the first Left Ventricular Assist Device (LVAD) with complete independent intellectual property rights approved by NMPA in China, and the first full magnetic levitation LVAD approved by NMPA.
From 9th to 14th of June 2019, the Gordon Research Conference was held in Barcelona, Spain. The conference theme this year was on Mechanical Circulatory Support (MCS) and brought together world-renowned doctors, scholars, and researchers in MCS field. Dr. Chen, CEO of the company, and Dr. Lin, CTO were invited to attend the conference and delivered a plenary speech.